Yamamoto Yui, Hanai Ko, Mori Tomomi, Yokoyama Yoichi, Yoshida Naoshi, Murata Hidekazu, Shinozaki Tomohiro, Babazono Tetsuya
Diabetes Center, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
Department of Information and Computer Technology, Faculty of Engineering, Tokyo University of Science, Tokyo, Japan.
Diabetologia. 2022 Jan;65(1):234-245. doi: 10.1007/s00125-021-05590-5. Epub 2021 Nov 5.
AIM/HYPOTHESIS: It remains unclear whether people with diabetes exhibiting non-albuminuric kidney insufficiency have higher risk of kidney function decline and mortality compared with those exhibiting preserved kidney function without albuminuria. Furthermore, information regarding the incidence of albuminuria in people with this unique phenotype is sparse. Here, we aimed to elucidate the risk of the kidney outcomes and all-cause mortality in people with diabetes exhibiting non-albuminuric kidney insufficiency.
In this retrospective cohort study, 8320 Japanese adults with type 2 diabetes were classified into four groups based on the presence of albuminuria and kidney insufficiency at baseline, defined as urinary albumin/creatinine ratio of equal to or above 30 mg/g and eGFR of less than 60 ml min 1.73 m, respectively. The primary composite kidney endpoint was a 50% decrease in eGFR from baseline or the initiation of kidney replacement therapy. The annual percentage change in eGFR slope and progression of albuminuria category were evaluated as the secondary and tertiary kidney endpoints, respectively. All-cause death was also set as the endpoint.
Compared with people exhibiting non-albuminuric preserved kidney function, those with non-albuminuric kidney insufficiency had the higher risk for the primary kidney endpoint (HR 4.1; 95% CI 2.5, 6.7; p < 0.001), steep percentage change in eGFR slope (-1.96%/year vs -1.36%/year, p < 0.001), incidence of albuminuria (HR 2.1; 1.7, 2.6; p < 0.001) and all-cause mortality (HR 1.5; 1.2, 2.0; p = 0.003). In the sensitivity analyses treating the incidence of albuminuria as a competing risk, people with non-albuminuric kidney insufficiency still had higher risk for the primary kidney endpoint and all-cause mortality than those with non-albuminuric preserved kidney function (subdistribution HR 2.8; 1.4, 5.6; p = 0.004; and 1.6; 1.1, 2.2; p = 0.014, respectively).
CONCLUSIONS/INTERPRETATION: People with type 2 diabetes exhibiting non-albuminuric kidney insufficiency had poorer kidney outcomes and life prognosis than those exhibiting non-albuminuric preserved kidney function.
目的/假设:与肾功能正常且无蛋白尿的人群相比,患有非蛋白尿性肾功能不全的糖尿病患者肾功能下降和死亡风险是否更高尚不清楚。此外,关于这种独特表型人群中蛋白尿发生率的信息也很稀少。在此,我们旨在阐明患有非蛋白尿性肾功能不全的糖尿病患者发生肾脏结局和全因死亡的风险。
在这项回顾性队列研究中,8320名日本成年2型糖尿病患者根据基线时是否存在蛋白尿和肾功能不全分为四组,分别定义为尿白蛋白/肌酐比值等于或高于30mg/g和估算肾小球滤过率(eGFR)低于60ml·min⁻¹·1.73m²。主要复合肾脏终点是eGFR较基线下降50%或开始肾脏替代治疗。eGFR斜率的年度百分比变化和蛋白尿类别进展分别作为次要和第三肾脏终点进行评估。全因死亡也被设定为终点。
与肾功能正常且无蛋白尿的人群相比,患有非蛋白尿性肾功能不全的人群发生主要肾脏终点的风险更高(风险比[HR]4.1;95%置信区间[CI]2.5,6.7;p<0.001),eGFR斜率的百分比变化更大(-1.96%/年对-1.36%/年,p<0.001),蛋白尿发生率更高(HR 2.1;1.7,2.6;p<0.001)以及全因死亡率更高(HR 1.5;1.2,2.0;p=0.003)。在将蛋白尿发生率视为竞争风险的敏感性分析中,患有非蛋白尿性肾功能不全的人群发生主要肾脏终点和全因死亡的风险仍高于肾功能正常且无蛋白尿的人群(分别为亚分布HR 2.8;1.4,5.6;p=0.004和1.6;1.1,2.2;p=0.014)。
结论/解读:患有非蛋白尿性肾功能不全的2型糖尿病患者的肾脏结局和生命预后比肾功能正常且无蛋白尿的患者更差。